Topics:

Gastrointestinal Cancer

Gastrointestinal Cancer

Two French studies have shown that screening for colorectal cancer with fecal occult blood tests can be very effective, according to results presented at the ESMO 2014 Congress.

Expression of the protein ALDH1A1 is associated with outcomes in gastric cancer, according to a new study, and could be used as a prognostic tool.

In this review, we summarize biologic, pathologic, and clinical aspects of gastroenteropancreatic-neuroendocrine tumors, focusing on recent advances in their treatment.

The relative abundance of new data on the biological underpinnings of neuroendocrine tumors, combined with clinical trial data supporting new treatment options, is a clear sign of progress. Yet, as is so often the case, these recent studies have generated a multitude of new and different questions.

In spite of recent encouraging developments in the setting of GI neuroendocrine tumors, many clinical questions remain to be answered and will be highlighted in this commentary.

In a preliminary study using a mouse model, researchers found that vagal denervation using Botox or other methods could help slow gastric cancer’s growth.

Adding cetuximab (Erbitux) to the standard first-line FOLFIRI chemotherapy regimen results in longer overall survival in metastatic colorectal cancer patients.

Pages

Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.